drug
monlunabant
Phase 2updated 3mo agoby Inversago Pharma Inc
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying monlunabant
News(2)
- Novo CEO sees innovation as a matter of survival amid pipeline setbacksNovo Nordisk CEO Maziar Mike Doustdar on a second quarter earnings call argued that failure is par for the course in the drug development business. The Danish pharma is focused on building out its…biospace · 15d ago
- Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataNovo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is…fiercebiotech · 15d ago
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that